Premium
Neurostimulation therapies in depression: a review of new modalities
Author(s) -
Marangell L. B.,
Martinez M.,
Jurdi R. A.,
Zboyan H.
Publication year - 2007
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.2007.01033.x
Subject(s) - vagus nerve stimulation , neurostimulation , deep brain stimulation , depression (economics) , transcranial magnetic stimulation , modalities , medicine , electroconvulsive therapy , treatment resistant depression , deep transcranial magnetic stimulation , neuromodulation , psychiatry , stimulation , brain stimulation , therapeutic modalities , neuroscience , psychology , vagus nerve , major depressive disorder , schizophrenia (object oriented programming) , physical therapy , disease , parkinson's disease , social science , cognition , sociology , economics , macroeconomics
Objective: In response to an increased understanding of the neurobiology of severe psychiatric disorders, new therapeutic modalities are entering clinical practice that involve the direct stimulation of the brain. Method: We provide a review of published literature regarding the clinical use of vagus nerve stimulation (VNS) therapy, transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) in psychiatric disorders, with an emphasis on treatment‐resistant depression (TRD). Results: Vagus nerve stimulation is approved for use in both the EU and US for TRD. TMS has been approved for TRD in Canada, Australia, New Zealand, the European Union and Israel, but not yet in the United States. DBS remains in the early stages of investigation. Conclusion: While additional studies are clearly warranted, treatments that directly stimulate the brain appear to hold great therapeutic promise for severe psychiatric disorders.